GNS Genus Plc

RNS Number:5425I
Genus PLC
27 November 2007

                                   Genus plc

                           ("Genus" or the "Company")



                          Animalcare Limited Disposal



Genus, a world leading animal genetics company, is pleased to announce that it
has entered into an agreement to dispose of Animalcare Limited ("Animalcare"),
its non-core veterinary pharmaceutical business, to Ritchey plc for a total cash
consideration of #14m, including a deferred element of #0.6m. The proceeds of
the disposal will be used to reduce debt.



The transaction is subject to financing which Ritchey plc plans to achieve
through a fundraising upon its admission to the AIM market. It is expected that
the transaction will complete on 10 January 2008. Payment of the #0.6m of
deferred consideration is conditional upon a manufacturing contract being set up
for a new product, currently under development.



For the year ended 30 June 2007, Animalcare generated an adjusted operating
profit of #1.6m. As at 30 June 2007 it had net assets of #6.7m.



For further information, please contact:
Genus plc                                                      Tel: 01256 345970
Richard Wood, Chief Executive
Martin Boden, Finance Director

Landsbanki Securities (UK) Limited                            Tel: 020 7426 9000
Financial Adviser & Joint Broker
Shaun Dobson

Buchanan Communications                                       Tel: 020 7466 5000
Charles Ryland / Suzanne Brocks



About Genus



Genus creates and sells added value products for livestock farming and food
producers by creating advances to animal breeding through biotechnology.  Its
non-Genetically Modified Organism (GMO) technology is applicable across all
livestock species but is only commercialised by Genus in the bovine and porcine
farming sectors.



Genus' worldwide sales are made in seventy countries under the trade marks "ABS"
(dairy and beef cattle) and "PIC" (pigs) and comprise semen and breeding animals
with superior genetics to those animals currently in production.  Customers use
Genus genetics on their herds to produce offspring with greater production
efficiency, milk and meat output and quality and use these to supply the global
dairy and meat supply chain.



Genus' competitive edge has been created from the ownership and control of
proprietary lines of breeding animals, the biotechnology used to improve them
and the Group's global production and distribution network.



Headquartered in Basingstoke, England, Genus companies operate in 30 countries
on five continents, with research laboratories located in Madison, USA.





                      This information is provided by RNS
            The company news service from the London Stock Exchange
END

DISFGMZMGVMGNZZ

Genus (LSE:GNS)
Historical Stock Chart
From Jun 2024 to Jul 2024

Genus (LSE:GNS)
Historical Stock Chart
From Jul 2023 to Jul 2024